Ancell Corporation will continue to supply our important Human Immunology research reagents to the research community as it endeavors to combat the spread of and develop a useful vaccine to the newly discovered deadly coronavirus (Covid-19). Ancell Corporation provides useful tools that allow research scientists to understand how this virus attacks the human immune system. This critical knowledge is needed to understand the best approach for vaccine development.
Ancell Corporation believes that it provides an essential function and will continue business under the “Exemptions- Critical Sectors” as stated by Minnesota Governor Tim Walz, Emergency Executive Order 20-20. Ancell Corporation will follow the “Guidance on the Essential Critical Infrastructure Workforce: Ensuring Community and National Resilience in COVID-19 Response” as directed in Version 1.1 (March 23, 2020) issued by the U.S. Department of Homeland Security.
John Orf, Ph.D.